(CBS/AP) The FDA moved closer to approving Xarelto (rivaroxaban) for the treatment of a heart condition that raises the risk for stroke when an advisory panel for the agency on Thursday green ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

Patients need to be tested regularly to be sure their blood is clotting at the safest level -- too much and a stroke can happen, not enough clotting and bleeding risks go up.

Xarelto (rivaroxaban), an anti-clotting medication, has been approved by the FDA for patients with non-valvular atrial fibrillation to reduce stroke risk.

The anti-clotting drug rivaroxaban helps lower the risk of heart attack, stroke and death in patients who are hospitalized for a heart attack or chest pain, according to a study released Sunday ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

June 18 -- WEDNESDAY, June 17 (HealthDay News) -- The new anti-clotting pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack and death in patients who have had a heart attack or ...

FDA approves two new indications for Xarelto ® (rivaroxaban) to help prevent and treat blood clots in pediatric patients. News release. Janssen Pharmaceutical Companies of Johnson & Johnson.

Anti-clotting drug significantly reduces bleeding events in patients with ... the team found that both doses of abelacimab almost eliminated gastrointestinal bleeding compared to rivaroxaban, ...

Research Highlights: Bleeding was reduced by more than 60% among people taking the anti-clotting agent abelacimab, demonstrating its safety for people at risk of stroke from atrial fibrillation.